Proliferation of Human Breast Cell Lines

1

H. Phillip Koeffler

expression of p27kip1. Compound LH is worthy of in vivo analysis for (NT7 M) induced elevated expression of p27Kipl in MCF-7 and SK-BR-3 mediated by LH is irreversible. The cyclin-dependent kinase inhibitor adequate to achieve a 50% inhibition of MCF-7 clonal growth in soft agar and decreasing those in the S phase of the cell cycle. Pulse-exposure cancer cells, increasing the proportion of MCF-7 cells in the G0-G1 phase, than 50% clonal proliferation (ED50) of the MCF-7 and SK-BR-3 breast as targets. Dose-response studies showed that each of the analogues had antiproliferative activities in several cell types. Six breast cancer cell lines were used as targets. Dose-response studies showed that each of the analogues had antiproliferative activities, and LH (1,25-(OH)2-16-ene-23-yne-26,27-F2, 19-nor D3) was the most potent analogue, suppressing at 10-11 M greater than 50% clonal proliferation (ED50) of the MCF-7 and SK-BR-3 breast cancer cells, increasing the proportion of MCF-7 cells in the G0-G1 phase, and decreasing those in the S phase of the cell cycle. Pulse-exposure studies showed that a 3-day exposure to LH (10-7 M) in liquid culture was adequate to achieve a 50% inhibition of MCF-7 clonal growth in soft agar in the absence of the analogue, suggesting that the growth inhibition mediated by LH is irreversible. The cyclin-dependent kinase inhibitor known as p27kip1 helps regulate the cell cycle and can mediate growth arrest in response to extracellular growth inhibitors. The analogue LH (10-7 M) induced elevated expression of p27kip1 in MCF-7 and SK-BR-3 cells. Taken together, these results indicate that LH is an extremely potent vitamin D3 analogue markedly inhibiting clonal growth of MCF-7 and SK-BR-3 cells with concomitant cell cycle arrest at G0-G1 and increased expression of p27kip1. Compound LH is worthy of in vivo analysis for possible future clinical trials.

INTRODUCTION

Breast cancer is the most common malignant disease of women in the United States. Improvement in hormonal and cytotoxic therapies have not led to either a major lengthening of remissions or increase in cures in advanced breast cancer. Antiestrogens have provided the most effective endocrine therapy for advanced breast cancer (1). The 1,25 D3 is a member of the seco-steroid family. Most breast cancer cell lines and more than 80% of breast tumors expressed high affinity VDRs (2-4). Reminiscent of estrogen receptor data, patients with primary carcinoma of the breast who were VDR positive had significant longer disease-free survival than those with VDR-negative tumors (5). The 1,25 D3 and its analogues inhibit proliferation of breast cancer cells in vitro (6-8). Likewise, 1,25 D3 and its related analogues decreased the progression of breast cancer and other carcinomas in vivo (9-11), inhibited metastatic spread of tumors cells (2, 12-14), and promoted differentiation of breast cancer cells as well as other varieties of cancer (5, 8, 15-18). However, the calcemic side effects of 1,25 D3 have prevented its application as a pharmaceutical agent. Synthesis of analogues of 1,25 D3 with potent antiproliferative and differentiation activity against cancer cells with decreased risk of inducing hypercalcemia has been reported (9, 11, 12, 19-21).

Previously, we have studied the in vitro biological activities and mechanism of action of four potent 1,25 D3 analogues (KH1060, 20-epi-1,25(OH)2-D3, 1,25(OH)2-16-ene-D3, and V) on the proliferation and differentiation of six breast cancer cell lines. In that study, KH1060 was the most potent 1,25 D3 analogue inhibiting clonal growth of four breast cancer lines, with decreased bcl-2 and cell cycle arrest at G0-G1 (22).

p27kip1 is a recently cloned cyclin-dependent kinase inhibitor associated with arrest of the cell cycle (23, 24). We have examined for p27kip1 mutations in 36 primary breast cancers and 9 breast cancer cell lines (25). Only two point mutations were found in the primary tumors. Additional studies showed that overexpressed Kip proteins caused cell cycle arrest, and expression of p27kip1 was up-regulated by exposure of the cells to several antimitotics (23, 26-30). In this study, we have shown that LH was the most potent of a new series of 1,25 D3 analogues in mediating the inhibition of clonal growth of MCF-7 and SK-BR-3 breast cancer cells associated with cell cycle arrest at G0-G1 and increased expression of p27kip1.19-nor-Hexafluoride Analogue of Vitamin D3: A Novel Class of Potent Inhibitors of Proliferation of Human Breast Cell Lines

Michiaki Koike,2 Elena Elstner, Moray J. Campbell, Hiroya Asou, Milan Uskokovic, Nobuyoshi Tsuruoka, and H. Phillip Koeffler

Division of Hematology/Oncology, Cedars-Sinai Research Institute, UCLA School of Medicine, Los Angeles, California 90048 [M. K., E. E., M. J. C. H. A., H. P. K.]; Hoffmann LaRoche, Inc., Nutley, New Jersey 07110 [M. U.]; and Department of Hematology, Showa University School of Medicine, Tokyo, Japan [N. T.]

ABSTRACT

Breast cancer cells express vitamin D3 receptors and 1,25-dihydroxyvitamin D3 suppressed growth of these cells. We have synthesized six novel vitamin D3 analogues to identify those with expanded capacity to inhibit the proliferative ability of breast cancer cells. These analogues incorporated many of the structural motifs shown previously to have antiproliferative activity in several cell types. Six breast cancer cell lines were used as targets. Dose-response studies showed that each of the analogues had antiproliferative activities, and LH (1,25-(OH)2-16-ene-23-yne-26,27-F2, 19-nor D3) was the most potent analogue, suppressing at 10-11 M greater than 50% clonal proliferation (ED50) of the MCF-7 and SK-BR-3 breast cancer cells, increasing the proportion of MCF-7 cells in the G0-G1 phase, and decreasing those in the S phase of the cell cycle. Pulse-exposure studies showed that a 3-day exposure to LH (10-7 M) in liquid culture was adequate to achieve a 50% inhibition of MCF-7 clonal growth in soft agar in the absence of the analogue, suggesting that the growth inhibition mediated by LH is irreversible. The cyclin-dependent kinase inhibitor known as p27kip1 helps regulate the cell cycle and can mediate growth arrest in response to extracellular growth inhibitors. The analogue LH (10-7 M) induced elevated expression of p27kip1 in MCF-7 and SK-BR-3 cells. Taken together, these results indicate that LH is an extremely potent vitamin D3 analogue markedly inhibiting clonal growth of MCF-7 and SK-BR-3 cells with concomitant cell cycle arrest at G0-G1 and increased expression of p27kip1. Compound LH is worthy of in vivo analysis for possible future clinical trials.

MATERIALS AND METHODS

Cell Lines. The breast cancer cell lines (MDA-MB-436, MCF-7, SK-BR-3, BT-474, BT-20, and MDA-MB-231) were obtained from American Type Culture Collection (Rockville, MD). The cells were cultured in DMEM or McCoy's media (Life Technologies, Inc., Grand Island, NY) containing 10% bovine fetal serum, according to the recommendations of American Type Culture Collection, in culture flasks with vented filter caps (Costar, Cambridge, MA).

Vitamin D3 Compounds. The vitamin D3 compounds were dissolved in absolute ethanol at 10-1 M as stock solution, which were stored at -20°C and protected from light. The analogues C, Y, LH, KS, KW, and LA were synthesized by Hoffmann LaRoche, Inc. (Fig. 1).

Clonogenic Assay in Soft Agar. Breast cancer cells were cultured in a two-layer soft agar system for 14 days, as described previously (31).

Pulse-Exposure Experiments. The MCF-7 cells were exposed to analogue LH (10-7 M) for various durations. After incubation, the cells were carefully washed twice, counted, and plated into 24-well plates for soft agar colony assay.

Cell Cycle Analysis by Flow Cytometry. Cell cycle analysis was performed on breast cancer cells incubated for 72 h with or without LH at 10-7 M. The methanol-fixed cells were incubated for 30 min at 4°C in the dark with a solution of 50 µg/ml propidium iodide, 1 mg/ml RNase (100 units/ml; Sigma Chemical Co.), and 0.1% NP40 (Sigma). Analysis was performed immediately after staining using the CELLFit program (Becton Dickinson), whereby the S phase was calculated with a Rfit model.

Western Blot Analysis. Cultured cells were washed twice with PBS and then lysed in 1 ml/107 cells of 50 mM Tris (pH 8.0), 150 mM NaCl, 0.1% SDS, 0.5% sodium deoxycholate, 1% NP40, 100 µg/ml phenylmethylsulfonyl fluoride, 2 µg/ml aprotinin, 1 µg/ml peptatin, and 10 µg/ml leupeptin for 30 min at 0°C. Insoluble material was removed by centrifugation at 14,000 rpm at 4°C.
VITAMIN D₃ ANALOGUES EFFECTIVE AGAINST BREAST CANCER

Fig. 1. Structures and code names of the novel vitamin D₃ analogues examined in this study.

for 10 min. Protein concentrations were determined using a Bio-Rad kit. Proteins (40 μg) were size fractionated under denaturing conditions on 12.5% SDS-running gel and transferred to Millipore membrane and exposed without drying to the X-ray film overnight. The p27Kip1-specific band was detected by Western blot hybridization of the membrane with purified anti-p27Kip1 antibody and detection of the signal was with the ECL system (Amersham). A rabbit polyclonal anti-serum specific for human p27Kip1 (Santa Cruz) was used for Western blot analysis.

RESULTS

Effect of Vitamin D₃ Analogues on Clonal Proliferation of Breast Cancer Cell Lines. Breast cancer cells were cloned in soft agar in the presence of vitamin D₃ analogues at 10⁻¹¹ to 10⁻⁷ M. Dose-response curves were drawn (Fig. 2), and the effective dose that inhibited 50% colony formation (ED₅₀) was determined (Table 1). The 1,25 D₃ analogues were effective in inhibition of clonal proliferation of two of the six breast cancer cell lines (MCF-7 and SK-BR-3; Fig. 2, a and b).

The BT-474 and MDA-MB-231 breast cancer cells were fairly resistant to the vitamin D₃ analogues, and the MDA-MB-436 and BT-20 were even more resistant (Fig. 2, c–f). For the two sensitive breast cancer cell lines (Fig. 2, a and b) as well as MDA-MB-231, the LH analogue was the most potent compound. The LH analogue achieved an ED₅₀ of 8 × 10⁻¹¹ and 8 × 10⁻¹⁰ M for SK-BR-3 and MCF-7, respectively (Table 1).

PULSE-EXPOSURE EXPERIMENTS. The MCF-7 cells were exposed to the analogue LH (10⁻⁷ M) for various durations, washed three times to remove the analogue, and plated in soft agar; and colony number was enumerated on day 14 (Fig. 3). Fifty % of the clonogenic cells were inhibited by 3 days of exposure to analogue LH, suggesting that this compound was capable of mediating an irreversible inhibition of the growth of these cells.

CELL CYCLE ANALYSIS. Effect of LH on the cell cycle of breast cancer cells was determined by studying the MCF-7 cells. These cells had a significant increase in the number of cells in the G₀-G₁ phase of the cell cycle (70 ± 2% with LH (10⁻⁷ M) for 72 h, 52 ± 1.7% in
Fig. 2. Dose-response effects of vitamin D₃ compounds on clonal proliferation of breast cancer cell lines. Results are expressed as a mean percentage of control plates containing no vitamin D₃ compounds (means of at least three experiments with triplicate dishes; bars, SD).

control cells] with a concomitant decrease in the S phase [16 ± 2% with LH (10⁻⁷ M) for 72 h, 35 ± 2.4% in control cells] (P < 0.05; Fig. 4).

Increased Levels of p27kip1 Induced in MCF-7 and SK-BR-3 Cell Lines during Exposure to Analogue LH. The MCF-7 and SK-BR-3 cells had a moderate level of expression of p27kip1 (Fig. 5, Lanes 2 and 4) as determined by Western blot analysis. Exposure of these cells to LH (10⁻⁷ M) resulted in a modest increase in expression of p27kip1 with levels increasing 40% in SK-BR-3 cell line at day 3 of exposure and 30% in MCF-7 cells at day 6 of exposure to the analogue (Fig. 5). Similar findings were found on repeat experiments.

4547
VITAMIN D₃ ANALOGUES EFFECTIVE AGAINST BREAST CANCER

Table 1 Inhibition of clonal proliferation of breast cancer cell lines by vitamin D₃ analogues

<table>
<thead>
<tr>
<th>Breast cancer cell lines</th>
<th>1,25 D₃</th>
<th>LA</th>
<th>LH</th>
<th>KS</th>
<th>KY</th>
<th>KW</th>
<th>V</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCF-7</td>
<td>3 x 10⁻⁸</td>
<td>1 x 10⁻⁸</td>
<td>8 x 10⁻¹⁰</td>
<td>8 x 10⁻⁸</td>
<td>8 x 10⁻⁹</td>
<td>1 x 10⁻⁸</td>
<td>5 x 10⁻⁸</td>
</tr>
<tr>
<td>SK-BR-3</td>
<td>8 x 10⁻⁹</td>
<td>3 x 10⁻⁸</td>
<td>8 x 10⁻¹¹</td>
<td>8 x 10⁻¹⁰</td>
<td>6 x 10⁻¹¹</td>
<td>8 x 10⁻¹⁰</td>
<td></td>
</tr>
<tr>
<td>BT-474</td>
<td>N.R.</td>
<td>N.R.</td>
<td>8 x 10⁻⁸</td>
<td>N.R.</td>
<td>N.R.</td>
<td>N.R.</td>
<td>N.R.</td>
</tr>
</tbody>
</table>

* Dose-response curves (Fig. 2) were used to calculate the concentration of the analogues achieving a 50% inhibition (ED₅₀) of clonal growth.

** N.R., the ED₅₀ was not reached at ≥10⁻⁷ M of the 1,25 D₃ analogue.

DISCUSSION

The six breast cancer cell lines used in our study varied in their sensitivities to the clonal inhibitory effects of the various 1,25 D₃ compounds. The most sensitive lines, MCF-7 and SK-BR-3, were inhibited by each of the analogues. In contrast, MDA-MB-436, BT-20, BT-474, and MDA-MB-231 cells were entirely or partially resistant to the 1,25 D₃ analogues used in this study, suggesting that preclinical testing of the breast cancer cells in vitro may be helpful in the selection of patients for clinical trials with these analogues.

The LH was the most active analogue in this study, which has double bonds at C16, triple bonds at C23, six fluorine substitutions at C26 and C27, and removal of a methylène at C19. Previously, we have shown that hexafluoro analogues of 1,25-(OH)₂D₃ were 5- to 350-fold more potent than 1,25 D₃ as antileukemic agents (21). LH was also very active against prostate cancer cell lines (LNCaP, PC-3, and DU-145 cell lines; Ref. 32).

Earlier, we have shown that a 20-epi-vitamin D₃ (KH-1060) was a very potent analogue against breast cancer cell lines (22). We synthesized a 20-epi-analogue (compound KY) that combined structural motifs shown previously to be important for antiproliferative activity against cancer cells (C16 and C23 double bonds, C26 and C27 hexa-fluorines). But, the addition of these structural elements to the 20-epi backbone did not increase antiproliferative activity (Fig. 2) as compared to the 20-epi form alone (22).

One of the interesting biologically and potentially clinically relevant observations that was made in this and another study done by us recently (33) is that cancer cells of different tissues can display different sensitivities to the same vitamin D₃ analogues. For example, analogue LA is one of the most potent analogues in its inhibition of clonal growth of HL60 leukemia cells, with an ED₅₀ of 2 x 10⁻¹¹ M, whereas analogue LH had an ED₅₀ of 2 x 10⁻¹⁰ M in the same assay. In contrast, analogue LA was 1 to 2 logs less effective than analogue LH in its antiproliferative activity against breast and prostate cancer cell lines (Table 1; Refs. 32 and 33). These results suggest that the mechanism of growth inhibition of cancer cells by vitamin D₃ analogues may vary between different types of tissues.

Pulse-exposure of MCF-7 cells for 3 days to analogue LH (10⁻⁷ M), washing, plating in soft agar, and enumerating colony formation 14 days after plating resulted in 50% inhibition of colony formation. These results suggest that LH inhibited growth of breast cancer cells by a mechanism other than one that is merely cytostatic. Furthermore, LH increased the number of MCF-7 cells in G₁ and decreased the number in S phase (Fig. 4).

Recently, several CDK inhibitor (CDK1) genes have been cloned, and they have been classified into two groups (34). One group includes the INK4 proteins: p16INK4A (35, 36); p15INK4B (36, 37–39); p18INK4C; and p19INK4D (39). These specifically inhibit the CDK complexes involving CDK4 and CDK6, which are CDKs expressed exclusively at the mid-G₁ phase of the cell cycle (34, 37, 39). The other group consists of p21WAF1 (40–45), p27KIP1 (23, 24), and p57KIP2 (46, 47). These proteins are structurally and functionally unrelated to the INK4 genes. The p27KIP1 protein has 42% amino acid homology with p21WAF1 and 47% similarity with the p57KIP2 protein within the NH₂-terminal domain, which mediates the inhibition of CDK (23, 24, 46–49). In comparison to the INK4 proteins, the

Fig. 3. Pulse-exposure of MCF-7 breast cancer cells to analogue LH. MCF-7 cells were exposed for various durations to analogue LH (10⁻⁷ M). The cells were then thoroughly washed three times and plated into soft agar. and colonies were counted 14 days after plating. Results are expressed as a mean percentage of control plates that received the same treatment but were not exposed to analogue (mean of three independent experiments; bars, SD).

Fig. 4. Cell cycle analysis of breast cancer cells that had been cultured with either compound C [1,25(OH)₂D₃] or analogue LH at 10⁻⁷ M for 3 days. Control cells represent those not exposed to vitamin D₃ compounds. Each point represents a mean of at least three independent experiments; bars, SD. * P ≤ 0.05 as determined by Student's t test difference from the control group.
p21p27p57 family shows a wide specificity and spectrum of inhibitory activities. All of these proteins are able to inhibit kinase activities of p21activated G1, cyclin E-cdk2 and cyclin D-cdk4/6, S-phase cyclin A-cdk2, as well as the mitotic cyclin B-cdc2 (26, 41, 46, 47). Overexpressed Kip proteins cause cell cycle arrest (23, 24, 48, 49). In a prior study, 1,25D3 (10−7 M, 48 h) caused a G1 to S-phase block in parallel with an increased abundance of p27Kip1 in HL-60 cells (30). In our study, the levels of p27Kip1 increased at day 3 of exposure of SK-BR-3 and day 6 of exposure of MCF-7 cells to analogue LH, supporting the hypothesis that the p27Kip1 protein may be one of the mediators of the antiproliferative activity of the vitamin D3 compounds by blocking entry of breast cancer cells into the S-phase.

In summary, we have identified a group of 1,25 D3 analogues, including LH, with potent antiproliferative effects on the MCF-7 and SK-BR-3 breast cancer cells in vitro. These interesting compounds will be studied for their ability to control the growth of breast cancers in vivo.

ACKNOWLEDGMENTS

We thank Peggy Palmer for excellent secretarial help.

REFERENCES


19-nor-Hexafluoride Analogue of Vitamin D₃: A Novel Class of Potent Inhibitors of Proliferation of Human Breast Cell Lines

Michiaki Koike, Elena Elstner, Moray J. Campbell, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/57/20/4545

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.